Catalog No.
DHH02214
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q15116
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
NPVPDR001, NVS240118, PDR001, CAS: 1935694-88-4
Clone ID
Spartalizumab
Antibodies to watch in 2020, PMID: 31847708
Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms, PMID: 33480358
Antibodies to watch in 2019, PMID: 30516432
PD-1 Blockade in Anaplastic Thyroid Carcinoma, PMID: 32364844
Recent advances in the management of anaplastic thyroid cancer, PMID: 33292371
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i, PMID: 33020648
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors, PMID: 32179633
Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies, PMID: 33031626
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer, PMID: 34433653
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas, PMID: 34389618
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors, PMID: 33883177
Mixed Reviews for A2AR Inhibitor in NSCLC, PMID: 30498135
Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer, PMID: 31978315
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma, PMID: 33686894
For research use only. Not for human or drug use.
